The China CNS therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of 7.3% during the forecast period.
A key trend in the market is pharma companies’ efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late-stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space.
The central nervous system therapeutic market is expected to register a high growth rate in the country owing to increasing prevalence of neurological disorders, increasing adoption of new generation drugs and growing awareness regarding psychiatric disorder. Also, changing social structures, and gradual reduction in the stigma associated with neurological disorders also contributes to the growth of CNS therapeutics market in china.